QS-21 + monophosphoryl lipid A
QS-21 + monophosphoryl lipid A has been studied in 1 paper since 2021: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Dec 18, 2021: “Comparison of the effects of different potent adjuvants on enhancing the immunogenicity and cross-protection by influenza virus vaccination in young and aged mice”.
See all 2 papers on QS-21 + monophosphoryl lipid A
At a glance
The findings reach mice, none yet in people. 1 lab in 1 country.
None of its findings points the other way.
- 1 lab in 1 country
- Funders: National Institute of Allergy and Infectious Diseases and 1 more
- Animals1
What did studies of QS-21 + monophosphoryl lipid A find?
2Studies of QS-21 + monophosphoryl lipid A measured 2 outcomes: weight loss and influenza.
Weight loss
downin mice1
1 study
Weight loss
downin mice1
QS-21 + monophosphoryl lipid A prevents weight loss in mice (influenza vaccination).
“Both combination adjuvants (QS-21+MPL and CpG+MPL) exhibited high potency by preventing weight loss”
Animalsinfluenza vaccination
Antiviral research
Influenza
downin mice1
1 study
Influenza
downin mice1
QS-21 + monophosphoryl lipid A protects against influenza in mice (influenza vaccination).
“enhanced homologous and cross-protection by influenza vaccination in adult and aged mouse models.”
Animalsinfluenza vaccination
Antiviral research